1063 patents
Utility
Combinatorial Drug Delivery Device
11 Jan 24
In one aspect, a combinatorial drug delivery device is provided for delivering a predetermined selection of drug components.
Martin John McLoughlin, Chester Larrow, Mariano Mumpower
Filed: 23 Sep 23
Utility
Methods of Treating Colon Cancer Using Nanoparticle Mtor Inhibitor Combination Therapy
11 Jan 24
The present application provides methods of treating a colon cancer (such as advanced and/or metastatic colon cancer) in an individual, comprising administering to the individual: a) an effective amount of a composition comprising nanoparticles comprising an mTOR inhibitor (such as a limus drug, such as sirolimus or a derivative thereof) and an albumin, b) an effective amount of anti-VEGF antibody (such as bevacizumab), and c) a therapeutically effective FOLFOX regimen (such as FOLFOX4 or a modified FOLFOX6).
Neil P. DESAI
Filed: 13 Apr 23
Utility
Substituted heterocyclic compounds
9 Jan 24
Steven H. Spergel, Ryan M. Moslin, Michael Edward Mertzman, Zili Xiao
Filed: 13 May 22
Utility
Naphthyridinone compounds useful as T cell activators
9 Jan 24
Louis S. Chupak, Min Ding, Robert G. Gentles, Yazhong Huang, Scott W. Martin, Ivar M. Mcdonald, Stephen E. Mercer, Richard E. Olson, Upender Velaparthi, Michael Wichroski, Xiaofan Zheng
Filed: 26 Jun 19
Utility
Oligomeric particle reagents and methods of use thereof
9 Jan 24
Provided herein are oligomeric reagents, including oligomeric reagents of streptavidin or a streptavidin mutein, compositions thereof, and methods for manufacturing oligomeric reagents, including methods for reliably manufacturing oligomeric particle reagents of a desired size.
Thomas Schmidt, Christian Stemberger, Tom Kowski, Ken Prentice
Filed: 27 Apr 18
Utility
Antibody Compositions and Methods of Use Thereof
4 Jan 24
The disclosure provides pharmaceutical compositions comprising an antibody and at least two antioxidants.
Masano HUANG, Thomas Arthur HABY, Mehrnaz KHOSSRAVI, Scott Aaron HART, Rao Venkatramana MANTRI, Heather Elizabeth VEZINA, Amit ROY, Bindu Purnima MURTHY, Urvi Ashish ARAS, Kinjal SANGHAVI, Xiaochen ZHAO, Akintunde BELLO
Filed: 21 Aug 23
Utility
Sulfone Pyridine Alkyl Amide-substituted Heteroaryl Compounds
4 Jan 24
CHUNJIAN LIU, MICHAEL G. YANG, ZILI XIAO, LING CHEN, RYAN M. MOSLIN, JOHN S. TOKARSKI, DAVID S. WEINSTEIN, STEPHEN T. WROBLESKI
Filed: 5 Sep 23
Utility
Cancer Immunotherapy by Disrupting PD-1/PD-L1 Signaling
4 Jan 24
The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway.
John P. COGSWELL, Stacie M. Goldberg, Ashok K. Gupta, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton
Filed: 2 Nov 22
Utility
Dosing and Administration of Non-fucosylated ANTI-CTLA-4 Antibody As Monotherapy
4 Jan 24
The present invention provides methods of dosing and administration of non-fucosylated anti-CTLA-4 antibodies, such as non-fucosylated ipilimumab, as monotherapy, and related compositions and dosage forms.
Leonard P. JAMES, Yougan CHENG, Brian J. SCHMDIT, John J. ENGELHARDT, Li LI
Filed: 5 Nov 21
Utility
Fibronectin based scaffold domain proteins that bind PCSK9
2 Jan 24
The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9.
Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
Filed: 16 Feb 21
Utility
Modified Fibroblast Growth Factor 21 (FGF-21) for Use In Methods for Treating Nonalcoholic Steatohepatitis (Nash)
28 Dec 23
Provided herein are methods for treating a patient having NASH who has been determined to have a particular threshold level of serum Pro-C3 (e.g., greater than 10 ng/ML) by administering to the patient a modified Fibroblast growth factor 21 (FGF-21) in an amount and with a frequency sufficient to treat NASH.
Edgar Davidson CHARLES, III, Rose C. CHRISTIAN, Yi LUO
Filed: 31 Mar 23
Utility
Process Toward the Manufacture of (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)-PYRIMIDINYL}- 1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15-(METHENO)PYRAZOLO[4,3-B][1,7]DIAZACYCLOTETRADECIN-5(6H)-ONE
28 Dec 23
Subha MUKHERJEE, William P. GALLAGHER, Christopher Robert JAMISON, Carolyn S. WEI, Sergei KOLOTUCHIN, Amarjit SINGH, Nicolas CUNIERE, Chris SFOUGGATAKIS, Adrian ORTIZ, Steven R. WISNIEWSKI, Bin ZHENG, Helen Y. LUO, Sébastien François Emmanuel LEMAIRE, Cyril BEN HAÏM, Kostiantyn CHERNICHENKO, Diego Fernando Domenico BROGGINI, Simon Albert WAGSCHAL, Duy Chi Trung CAO, Karl REUTER, Björn SCHMALZBAUER, Philipp KOSCHKER, Martin D. EASTGATE, Dimitri SKLIAR, Alexander ZHDANKO, Christos XIOURAS, Matthew Penfield MOWER, Ngoc Duc TRAN, Ramdane RAHMANI, Xavier Jean-Marie JUSSEAU, Kiran MATCHA, Luca Alessandro PEREGO
Filed: 11 Oct 21
Utility
Methods of Redirecting of IL-2 to Target Cells of Interest
28 Dec 23
The present disclosure provides constructs comprising an anti-PDI antibody, or an alternative targeting moiety, fused to CD25 or an IL-2 binding fragment of CD25.
Flavio SCHWARZ, Xiaodi DENG, Pavel STROP
Filed: 12 Aug 21
Utility
Treatment of Cancer with Anti-gitr Agonist Antibodies
28 Dec 23
Provided herein are methods for treating cancer, comprising administering to a subject having cancer a therapeutically effective amount of an anti-GITR antibody alone or together with an anti-PD-1 or anti-PD-L1 antibody.
Suba KRISHNAN, Penny E. PHILLIPS, Zheng YANG, Haiqing WANG
Filed: 12 Apr 23
Utility
Medical Imaging Analysis Using Self-supervised Learning
21 Dec 23
A method includes obtaining a first training data set including unannotated multi-dimensional medical images and executing a self-supervised masked image modeling (MIM) training process to pre-train an image encoder on the first training data set.
Zekai Chen, Kevin Alex Brown
Filed: 20 Apr 23
Utility
Miniaturized Dystrophins Having Spectrin Fusion Domains and Uses Thereof
21 Dec 23
Disclosed herein are nucleic acid molecules, polypeptides, cells, vectors, and pharmaceutical compositions relating to miniaturized dystrophin.
Glen B. Banks, Jonathan Harry Davis, Paul Charles Levesque
Filed: 2 Nov 22
Utility
Classifying Pharmacovigilance Documents Using Image Analysis
21 Dec 23
Provided herein are systems, apparatus, device, method, and/or computer program product embodiments, and/or combinations and sub-combinations thereof, for classifying a document using image analysis.
Sameen Mayur Desai
Filed: 28 Aug 23
Utility
System for verifying accuracy of serially-connected drug modules in a combinatorial drug delivery device
19 Dec 23
In one aspect, a system is provided of verifying the accuracy of a plurality of serially-connected drug modules of a combinatorial drug delivery device, each of the drug modules including a drug reservoir, the system including: a machine-readable code located on each of the drug modules; application software configured to generate an activation code based on the machine-readable codes and the sequence of the machine-readable codes; a flow controller on the drug delivery device which is selectively actuatable to a use state to permit flow of drug from the drug delivery device; and, a control unit on the drug delivery device having a computing processing unit configured to compare the activation code with an authentication code, and, wherein, if the authentication code matches the activation code, the computing processing unit causes actuation of the flow controller to permit flow of the drug from the drug delivery device.
Martin John McLoughlin
Filed: 21 Oct 20
Utility
Cation exchange resins
12 Dec 23
In some embodiments, the present invention provides a method of purifying a protein of interest with a reduced level of aggregation formation in cation exchange (CEX) chromatography, comprising: (a) providing a mixture comprising the protein of interest and one or more contaminants; (b) loading the mixture onto a CEX resin coupled with arginine; and (c) eluting the protein of interest from the resin, thereby purifying the protein of interest with a reduced level of aggregation formation in CEX chromatography.
Zhengjian Li, Xuankuo Xu, Chao Huang, Zhiqiang Chen
Filed: 10 Feb 21
Utility
Carbamoyloxymethyl Triazole Cyclohexyl Acids As
Lpa Antagonists
7 Dec 23
Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Babu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
Filed: 22 Aug 23